BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feitz WJC, van de Kar NCAJ, Orth-Höller D, van den Heuvel LPJW, Licht C. The genetics of atypical hemolytic uremic syndrome. Med Genet 2018;30:400-9. [PMID: 30930551 DOI: 10.1007/s11825-018-0216-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Pollack S, Eisenstein I, Mory A, Paperna T, Ofir A, Baris-Feldman H, Weiss K, Veszeli N, Csuka D, Shemer R, Glaser F, Prohászka Z, Magen D. A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report. Front Immunol 2021;12:608604. [PMID: 34248927 DOI: 10.3389/fimmu.2021.608604] [Reference Citation Analysis]
2 Song H, Zhang M, Li X, Xu F, Zhang D, Zhu X, Zhang J, Qin W, Shi S, Wen J. Generation and Characterization of Mouse Models of C3 Glomerulonephritis With CFI D288G and P467S Mutations. Front Physiol 2021;12:649801. [PMID: 34149444 DOI: 10.3389/fphys.2021.649801] [Reference Citation Analysis]
3 Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C, Ter Heine R, Volokhina EB, Van Den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Front Immunol 2020;11:612706. [PMID: 33519821 DOI: 10.3389/fimmu.2020.612706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
5 Abazi-Emini N, Sahpazova E, Putnik J, Tasic V. Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome: A Case Report. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021;42:109-15. [PMID: 34699711 DOI: 10.2478/prilozi-2021-0029] [Reference Citation Analysis]
6 Kelleher C, Kocinsky H. Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease. Adv Chronic Kidney Dis 2020;27:95-103. [PMID: 32553251 DOI: 10.1053/j.ackd.2020.02.006] [Reference Citation Analysis]
7 Kurian CJ, French Z, Kukulich P, Lankiewicz M, Ghimire S, Maarouf OH, Rizk S, Rhoades R. Case series: coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: two case reports. J Med Case Rep 2021;15:587. [PMID: 34903272 DOI: 10.1186/s13256-021-03144-2] [Reference Citation Analysis]
8 Ersoy Dursun F, Yesil G, Sasak G, Dursin H. Familial Atypical Hemolytic Uremic Syndrome with Positive p.S1191L (c.3572C>T) Mutation on the CFH Gene: A Single-center Experience. Balkan J Med Genet 2021;24:81-8. [PMID: 34447663 DOI: 10.2478/bjmg-2021-0007] [Reference Citation Analysis]
9 Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-12. [PMID: 33683339 DOI: 10.1182/bloodadvances.2020003175] [Reference Citation Analysis]